#United States #Ledger Run #Gary Lubin #John Chinnici #Tiburon

Leadership Transition at Ledger Run

Ledger Run, renowned for its innovative software solutions tailored for clinical trials, has announced a significant leadership change. Gary Lubin, the founder and long-standing CEO, is set to retire on March 1, 2025, passing the leadership to John Chinnici, a seasoned executive with extensive experience in the life sciences sector.

Having established Ledger Run as a key player in the clinical trial operations arena, Lubin leaves behind a legacy of growth and innovation. Under his guidance, the company has expanded its footprint globally, working with over 20,000 clinical sites across more than 40 countries and supporting over a thousand active studies on its cutting-edge ClinRun™ platform. His commitment to fostering a customer-first culture has engendered a highly engaged workforce dedicated to advancing medical research.

During his 40-year career, Lubin has been instrumental in numerous transformative efforts within the industry. "It has been an honor to lead Ledger Run, and I am optimistic about the future under John’s leadership," he stated, highlighting the strength of the team and the potential for continued improvement in their technology offerings.

New CEO's Vision

John Chinnici, who takes over the reins as CEO, brings over 25 years of experience in scaling software solutions, particularly in the life sciences sector. His professional journey includes substantial roles at notable companies like Accenture, IBM, and Veeva Systems, where he contributed significantly to growth during pivotal moments.

Chinnici expressed excitement about stepping into this new role. "I look forward to building upon the incredible legacy that Gary has created and to serving Ledger Run's esteemed clientele. The blend of talented people and advanced technology here promises a bright future for the company," he commented.

A Culture of Innovation

The Board of Directors has publicly acknowledged Gary Lubin's contributions to the company's success, emphasizing his vision, leadership, and commitment to fostering a collaborative environment. John Durrett, a member of the Board and Partner at Blue Star Innovation Partners, stated, "Gary's dedication to innovative technologies and creative culture has significantly shaped Ledger Run's trajectory. We are excited about John joining Ledger Run and leading us into our next growth phase."

As the company prepares for this transition, it aims to maintain its focus on transforming clinical trial operations through its trailblazing software solutions. ClinRun, Ledger Run's flagship product, automates many tasks typically undertaken manually, thereby reducing errors, accelerating processes, and enhancing collaboration among sponsors, Contract Research Organizations (CROs), and investigator sites. This ease of implementation allows Ledger Run to tackle the most complex of clinical trials effectively.

Looking Forward

With John Chinnici at the helm, Ledger Run is poised for further significant growth in the clinical trials domain. As the company continues to evolve, it remains committed to its core mission of enhancing the effectiveness and efficiency of clinical research, thereby supporting the development of new medical therapies. The team looks forward to building upon the solid foundation laid by Lubin while embracing innovative solutions to meet the growing needs of the healthcare industry.

For those interested in learning more about Ledger Run and its commitment to advancing clinical trial technologies, please visit www.ledgerrun.com.